North America Chinese Hamster Ovary Cells Cho Market
市场规模（十亿美元）
CAGR :
% 
 Forecast Period |
2023 –2030 |
 Market Size (Base Year) |
USD 143,106.10 Thousand |
 Market Size (Forecast Year) |
USD 263,069.07 Thousand |
 CAGR |
% |
| Major Markets Players |
>北美中国仓鼠卵巢 (CHO) 细胞市场，按类型（服务和产品）、系统（代谢选择系统、抗生素选择系统等）、应用（生物制剂和医学研究）、最终用户（生物制药公司、生物技术公司、临床开发和制造组织、临床研究组织、学术机构和研究组织等）、分销渠道（直接招标、零售销售等）划分 - 行业趋势和预测到 2030 年。
北美中国仓鼠卵巢 (CHO) 细胞市场分析与洞察
CHO 细胞市场的一个重要驱动因素是制药行业单克隆抗体(mAb) 的持续增长。CHO 细胞是生产 mAb 不可或缺的部分，mAb 可治疗各种疾病，包括癌症和自身免疫性疾病。基于 mAb 的疗法的扩展和该领域的持续研究和开发推动了对 CHO 细胞的需求。市场还受益于增加研发工作以改进细胞系开发和生物过程优化。这些进步有助于提高基于 CHO 细胞的生物制造的效率和生产力，从而降低生产成本和时间。
然而，市场面临着维持 CHO 培养的成本高、缺乏熟练人员以及监管要求复杂等挑战。
北美中国仓鼠卵巢 (CHO) 细胞市场预计将在 2023 年至 2030 年的预测期内实现市场增长。Data Bridge Market Research 分析称，在 2023 年至 2030 年的预测期内，该市场将以 8.3% 的复合年增长率增长，预计到 2030 年将从 2022 年的 143,106.10 万美元达到 263,069.07 万美元。
|
报告指标 |
细节 |
|
预测期 |
2023 至 2030 年 |
|
基准年 |
2022 |
|
历史岁月 |
2021 (可定制为 2015-2020) |
|
定量单位 |
收入（千美元）、平均售价（美元）和销量（单位） |
|
涵盖的领域 |
类型（服务和产品）、系统（代谢选择系统、抗生素选择系统等）、应用（生物制剂和医学研究）、最终用户（生物制药公司、生物技术公司、临床开发和制造组织、临床研究组织、学术机构和研究组织等）、分销渠道（直接招标、零售等） |
|
覆盖国家 |
美国、加拿大和墨西哥 |
|
涵盖的市场参与者 |
Thermo Fisher Scientific Inc.、AcceGen、RayBiotech Life, Inc.、CLS Cell Lines Service GmbH、BPS Bioscience, Inc.、GenTarget Inc.、Merck KGaA、Promega Corporation、Abeomics、Applied Biological Materials Inc. (abm)、ATCC、Sartorius AG、Lonza、Horizon Discovery Ltd.、Cytiva 和 Curia Global, Inc. |
北美中国仓鼠卵巢 (CHO) 细胞市场定义
中国仓鼠卵巢 (CHO) 细胞是一种哺乳动物细胞系，常用于生物技术和生物医学研究，尤其是细胞培养和生物加工。这些细胞已成为生物技术和生物医学研究中必不可少的工具。CHO 细胞以其对培养表面的粘附性、强劲的生长特性和表达重组蛋白的能力而闻名。它们之所以受欢迎，是因为它们与人类细胞相似，适合研究生物过程和生产生物制药。
北美中国仓鼠卵巢 (CHO) 细胞市场动态
本节旨在了解市场驱动因素、优势、限制和挑战。下面将详细讨论所有这些内容：
驱动程序
- CHO 细胞在遗传研究中的应用日益广泛
CHO 细胞是源自中国仓鼠卵巢的上皮细胞系，常用于生物和医学研究，并用于商业生产治疗性重组 DNA 蛋白。它们已广泛应用于遗传学、毒性筛选、营养学和基因表达研究，尤其是重组蛋白表达。CHO 细胞是重组蛋白药物工业生产中最常用的哺乳动物宿主。
CHO细胞在遗传学研究中的广泛应用体现了其在遗传学研究中的独特优势。
CHO 细胞以其遗传稳定性而闻名。这意味着它们的基因组成在多个细胞代中保持相对稳定，使其成为遗传研究的绝佳选择。研究人员可以放心地操纵和研究特定基因或遗传修饰，而不必担心意外的遗传变化会干扰他们的实验。这种稳定性在进行精确的基因编辑、敲除研究或研究遗传修饰的长期影响时尤为重要。
- 生物制药需求不断增长
生物制药需求的一个重要驱动因素是其有效性。这些药物在肿瘤学、自身免疫性疾病和罕见遗传病方面表现出了显著的治疗效果。例如，单克隆抗体是一种常见的生物制药，它通过直接靶向癌细胞同时保留健康细胞，彻底改变了癌症治疗。生物制药还为治疗以前无法治愈的疾病和罕见疾病提供了有希望的方法，而这些疾病和罕见疾病由于患者人数有限而经常被传统药物开发所忽视。
机会
-
细胞培养技术的不断发展
细胞培养技术的不断发展在生物制药生产和生物技术研究领域至关重要。这一持续的演变对于提高各种关键产品的产量至关重要，包括生物药物、疫苗和其他生物技术物质。细胞培养技术涉及在受控环境（通常是实验室环境）中培养和维持来自活生物体的细胞。这些培养的细胞是生产各种生物制药和生物技术产品的基础构件。这一进步的意义在于它能够提供可扩展且一致的细胞来源，这些细胞可以通过基因改造来表达特定的蛋白质或治疗剂。这些培养的细胞是单克隆抗体、疫苗、基因疗法和 再生药物等生物制剂不可或缺的一部分。细胞培养技术的不断改进可提高产量、提高效率、降低生产成本和改善产品质量，最终使医疗行业和依赖这些创新疗法的患者都受益。此外，它促进了生物技术研究新前沿的探索，使科学家能够研究细胞行为、疾病机制和药物开发，最终突破科学知识和医学进步的界限。
限制/挑战
-
基于 CHO 细胞的生产成本高
中国仓鼠卵巢 (CHO) 细胞生产成本高是生物制药制造业的一大制约因素。多种因素导致成本高昂。
CHO 细胞生产的上游过程非常复杂。它涉及在生物反应器中培养哺乳动物细胞，需要严格控制温度、pH、氧气水平和营养供应等各种参数。维持这些细胞生长和蛋白质表达的最佳条件需要专门的设备和熟练的人员，这会增加总体成本。
- CHO 细胞系开发过程耗时且不一致
用于生物制药生产的 CHO 细胞系的开发是一个复杂且耗时的过程，通常具有可变性和挑战性。该过程从将特定基因或遗传修饰引入 CHO 细胞开始，使其能够表达和生产所需的生物药物或蛋白质。然而，这个初始步骤可能效率低下，因为并非所有细胞都能成功整合遗传物质，从而导致蛋白质表达水平不稳定。
最新动态
- 2023 年 7 月，Lonza 推出了 TheraPRO CHO 培养基系统，这是一种新型细胞培养基，在使用 GS-CHO 细胞系时可简化流程并优化生产力和蛋白质质量。这家初创公司支持生产治疗性蛋白质的制药和生物技术公司进一步提高产品质量。TheraPRO CHO 培养基系统提供高效的性能，在 15 天的培养期内可实现高浓度的活细胞和高于 5 g/L 的蛋白质滴度。这相当于使用市售解决方案可生产的蛋白质滴度的两倍以上。此次发布帮助该公司扩大了其在市场上的产品组合。
- 2023 年 7 月，默克宣布将扩建位于美国堪萨斯州莱尼克萨的工厂，增加 9,100 平方米的实验室空间和生产细胞培养基的生产能力。此次扩建使莱尼克萨成为该公司最大的干粉细胞培养设施和北美卓越中心。对该地区的投资反映了该公司扩大和多样化其供应链的战略，以满足当前和未来对细胞培养平台的需求。
- 2023 年 6 月，领先的合同研究、开发和制造公司 Curia 宣布已与位于德国达姆施塔特的北美生命科学公司 MilliporeSigma、Merck KGaA 签署了许可协议，该协议将允许 Curia 及其客户使用 CHOZN GS-/- 细胞系生产用于治疗目的的蛋白质和抗体。协议达成后，CHOZN GS-/- 细胞系将整合到 Curia 的细胞系开发工作流程中，并立即可供 Curia 的客户使用。
- 2022 年 10 月，Thermo Fisher Scientific Inc. 与 ProBioGen 合作开发了一个更好的平台 Gibco Freedom ExpiCHO-S 细胞系开发试剂盒。该试剂盒允许用户生成适合临床开发的细胞系，而无需自己的原始细胞、载体或该领域的先前经验。ProBioGen 利用其在细胞系和工艺开发方面的强大专业知识，为 Freedom ExpiCHO-S 试剂盒的性能做出了重大贡献。新系列利用 Thermo Fisher 的 ExpiCHO-S 细胞系，扩大了公司针对 CHO 细胞系开发系列的产品组合。
- 2022 年 2 月，Sartorius AG 收购了 Novasep 的业务，为其色谱产品组合增加了补充产品。收购的产品组合包括主要适用于寡核苷酸、肽和胰岛素等小生物分子的色谱系统，以及用于连续生产生物制药的创新系统。
北美中国仓鼠卵巢 (CHO) 细胞市场范围
北美中国仓鼠卵巢 (CHO) 细胞市场根据类型、系统、应用、最终用户和分销渠道分为五个显著的细分市场。细分市场之间的增长有助于您分析利基增长领域和进入市场的策略，并确定您的核心应用领域和目标市场的差异。
类型
- 服务
- 产品
根据类型，市场分为服务和产品。
系统
- 代谢选择系统
- 抗生素选择系统
- 其他的
根据系统，市场分为代谢选择系统、抗生素选择系统和其他系统。
应用
- 生物制剂
- 医学研究
根据应用，市场分为生物制剂和医学研究。
最终用户
- 生物制药公司
- 生物科技公司
- 临床开发和制造组织
- 临床研究组织
- 学术机构和研究组织
- 其他的
根据最终用户，市场细分为生物制药公司、生物技术公司、临床开发和制造组织、临床研究组织、学术机构和研究组织等。
分销渠道
- 直接招标
- 零售销售
- 其他的
根据分销渠道，市场分为直接招标、零售和其他。
北美中国仓鼠卵巢 (CHO) 细胞市场区域分析/见解
市场分为五个显著的部分，例如类型、系统、应用、最终用户和分销渠道。
本市场报告涵盖的国家包括美国、加拿大和墨西哥。
由于美国是最大的消费市场，GDP 较高，且 CHO 细胞产品的技术进步不断提升，因此预计美国将占据主导地位。
报告的国家部分还提供了影响市场当前和未来趋势的各个市场影响因素和国内市场监管变化。新销售、替代销售、国家人口统计、监管法案和进出口关税等数据点是用于预测各个国家市场情景的一些主要指标。此外，在对国家数据进行预测分析时，还考虑了区域品牌的存在和可用性以及它们因来自本地和国内品牌的激烈或稀缺竞争而面临的挑战，以及销售渠道的影响。
竞争格局和北美中国仓鼠卵巢 (CHO) 细胞市场份额分析
北美中国仓鼠卵巢 (CHO) 细胞市场竞争格局按竞争对手提供详细信息。详细信息包括公司概况、公司财务状况、收入、市场潜力、研发投资、新市场计划、生产基地和设施、公司优势和劣势、产品发布、产品批准、产品宽度和广度、应用优势、产品类型生命线曲线。以上数据点仅与公司对市场的关注有关。
北美中国仓鼠卵巢 (CHO) 细胞市场的一些主要参与者包括 Thermo Fisher Scientific Inc.、AcceGen、RayBiotech Life, Inc.、CLS Cell Lines Service GmbH、BPS Bioscience, Inc.、GenTarget Inc.、Merck KGaA、Promega Corporation、Abeomics、Applied Biological Materials Inc. (abm)、ATCC、Sartorius AG、Lonza、Horizon Discovery Ltd.、Cytiva 和 Curia Global, Inc. 等。
SKU-
Get online access to the report on the World's First Market Intelligence Cloud
- Interactive Data Analysis Dashboard
- Company Analysis Dashboard for high growth potential opportunities
- Research Analyst Access for customization & queries
- Competitor Analysis with Interactive dashboard
- Latest News, Updates & Trend analysis
- Harness the Power of Benchmark Analysis for Comprehensive Competitor Tracking
目录
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF THE NORTH AMERICA CHINESE HAMSTER OVARY (CHO) CELLS MARKET
1.4 LIMITATIONS
1.5 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 MARKETS COVERED
2.2 GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 CURRENCY AND PRICING
2.5 DBMR TRIPOD DATA VALIDATION MODEL
2.6 MULTIVARIATE MODELLING
2.7 TREATMENT LIFELINE CURVE
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.9 DBMR MARKET POSITION GRID
2.1 MARKET APPLICATION COVERAGE GRID
2.11 VENDOR SHARE ANALYSIS
2.12 SECONDARY SOURCES
2.13 ASSUMPTIONS
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
4.1 PESTEL ANALYSIS
4.2 PORTER’S FIVE FORCES
5 NORTH AMERICA CHINESE HAMSTER OVARY CELLS (CHO) MARKET, REGULATIONS
6 MARKET OVERVIEW
6.1 DRIVERS
6.1.1 RISING USE OF CHO CELLS IN THE GENETIC STUDY
6.1.2 GROWING DEMAND FOR BIOPHARMACEUTICALS
6.1.3 RISING INVESTMENTS IN BIOTECHNOLOGY R&D
6.1.4 RISING DEMAND FOR MONOCLONAL ANTIBODIES
6.2 RESTRAINTS
6.2.1 HIGH-COST OF CHO CELL-BASED PRODUCTION
6.2.2 STRICT REGULATORY REQUIREMENTS FOR CHO CELL-BASED PRODUCTION
6.3 OPPORTUNITIES
6.3.1 CONTINUOUS DEVELOPMENT OF CELL CULTURE TECHNOLOGIES
6.3.2 RISING NUMBER OF APPLICATIONS OF CHO CELLS
6.4 CHALLENGES
6.4.1 TIME-CONSUMING AND INCONSISTENCY IN THE CHO CELL LINE DEVELOPMENT PROCESS
6.4.2 CONTAMINATION RISK OF CHO CELL CULTURES
7 NORTH AMERICA CHINESE HAMSTER OVARY (CHO) CELLS MARKET, BY TYPE
7.1 OVERVIEW
7.2 SERVICES
7.3 PRODUCT
7.3.1 CHO-DXB11
7.3.2 CHO-K1
7.3.2.1 CHO-K1 ATCC
7.3.2.2 CHO-K1 ECACC
7.3.2.3 OTHERS
7.3.3 CHO-DG44
7.3.4 CHO-S
7.3.5 OTHERS
8 NORTH AMERICA CHINESE HAMSTER OVARY (CHO) CELLS MARKET, BY SYSTEM
8.1 OVERVIEW
8.2 METABOLIC SELECTION SYSTEM
8.3 ANTIBIOTIC SELECTION SYSTEM
8.4 OTHERS
9 NORTH AMERICA CHINESE HAMSTER OVARY (CHO) CELLS MARKET, BY APPLICATION
9.1 OVERVIEW
9.2 BIOLOGICS
9.2.1 MONOCLONAL ANTIBODIES
9.2.2 ENZYMES
9.2.3 CYTOKINES
9.2.4 CLOTTING FACTORS
9.2.5 HORMONES
9.2.6 FC-FUSION PROTIEN
9.2.7 OTHERS
9.3 MEDICAL RESEARCH
10 NORTH AMERICA CHINESE HAMSTER OVARY (CHO) CELLS MARKET, BY END USER
10.1 OVERVIEW
10.2 BIOPHARMACEUTICAL COMPANIES
10.2.1 MEDIUM
10.2.2 SMALL
10.3 BIOTECHNOLOGY COMPANIES
10.3.1 MEDIUM
10.3.2 SMALL
10.4 CLINICAL DEVELOPMENT AND MANUFACTURING ORGANIZATIONS
10.4.1 MEDIUM
10.4.2 SMALL
10.5 CLINICAL RESEARCH ORGANIZATIONS
10.5.1 MEDIUM
10.5.2 SMALL
10.6 ACADEMIC INSTITUTES AND RESEARCH ORGANIZATIONS
10.7 OTHERS
11 NORTH AMERICA CHINESE HAMSTER OVARY (CHO) CELLS MARKET, BY DISTRIBUTION CHANNEL
11.1 OVERVIEW
11.2 DIRECT TENDERS
11.3 RETAIL SALES
11.4 OTHERS
12 NORTH AMERICA CHINESE HAMSTER OVARY (CHO) CELLS MARKET BY COUNTRY
12.1 NORTH AMERICA
12.1.1 U.S.
12.1.2 CANADA
12.1.3 MEXICO
13 NORTH AMERICA CHINESE HAMSTER OVARY (CHO) CELLS MARKET, COMPANY LANDSCAPE
13.1 COMPANY SHARE ANALYSIS: NORTH AMERICA
14 SWOT ANALYSIS
15 COMPANY PROFILE
15.1 LONZA
15.1.1 COMPANY SNAPSHOT
15.1.2 REVENUE ANALYSIS
15.1.3 PRODUCT PORTFOLIO
15.1.4 RECENT DEVELOPMENT
15.2 SARTORIUS AG
15.2.1 COMPANY SNAPSHOT
15.2.2 REVENUE ANALYSIS
15.2.3 PRODUCT PORTFOLIO
15.2.4 RECENT DEVELOPMENT
15.3 MERCK KGAA
15.3.1 COMPANY SNAPSHOT
15.3.2 REVENUE ANALYSIS
15.3.3 PRODUCT PORTFOLIO
15.3.4 RECENT DEVELOPMENT
15.4 CYTIVA
15.4.1 COMPANY SNAPSHOT
15.4.2 PRODUCT PORTFOLIO
15.4.3 RECENT DEVELOPMENT
15.5 THERMO FISHER SCIENTIFIC INC.
15.5.1 COMPANY SNAPSHOT
15.5.2 REVENUE ANALYSIS
15.5.3 PRODUCT PORTFOLIO
15.5.4 RECENT DEVELOPMENT
15.6 ABEOMICS
15.6.1 COMPANY SNAPSHOT
15.6.2 PRODUCT PORTFOLIO
15.6.3 RECENT DEVELOPMENT
15.7 ACCEGEN
15.7.1 COMPANY SNAPSHOT
15.7.2 PRODUCT PORTFOLIO
15.7.3 RECENT DEVELOPMENT
15.8 APPLIED BIOLOGICAL MATERIALS INC. (ABM)
15.8.1 COMPANY SNAPSHOT
15.8.2 PRODUCT PORTFOLIO
15.8.3 RECENT DEVELOPMENT
15.9 ATCC
15.9.1 COMPANY SNAPSHOT
15.9.2 PRODUCT PORTFOLIO
15.9.3 RECENT DEVELOPMENT
15.1 BPS BIOSCIENCE, INC.
15.10.1 COMPANY SNAPSHOT
15.10.2 PRODUCT PORTFOLIO
15.10.3 RECENT DEVELOPMENT
15.11 CLS CELL LINES SERVICE GMBH
15.11.1 COMPANY SNAPSHOT
15.11.2 PRODUCT PORTFOLIO
15.11.3 RECENT DEVELOPMENT
15.12 CURIA GLOBAL, INC.
15.12.1 COMPANY SNAPSHOT
15.12.2 PRODUCT PORTFOLIO
15.12.3 RECENT DEVELOPMENT
15.13 GENTARGET INC.
15.13.1 COMPANY SNAPSHOT
15.13.2 PRODUCT PORTFOLIO
15.13.3 RECENT DEVELOPMENT
15.14 HORIZON DISCOVERY LTD.
15.14.1 COMPANY SNAPSHOT
15.14.2 PRODUCT PORTFOLIO
15.14.3 RECENT DEVELOPMENT
15.15 PROMEGA CORPORATION
15.15.1 COMPANY SNAPSHOT
15.15.2 PRODUCT PORTFOLIO
15.15.3 RECENT DEVELOPMENT
15.16 RAYBIOTECH LIFE, INC.
15.16.1 COMPANY SNAPSHOT
15.16.2 PRODUCT PORTFOLIO
15.16.3 RECENT DEVELOPMENT
16 QUESTIONNAIRE
17 RELATED REPORTS
表格列表
TABLE 1 NORTH AMERICA CHINESE HAMSTER OVARY (CHO) CELLS MARKET, BY TYPE, 2022-2030 (USD THOUSAND)
TABLE 2 NORTH AMERICA PRODUCT IN CHINESE HAMSTER OVARY (CHO) CELLS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 3 NORTH AMERICA CHINESE HAMSTER OVARY (CHO) CELLS MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)
TABLE 4 NORTH AMERICA CHO-K1 IN CHINESE HAMSTER OVARY (CHO) CELLS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 5 NORTH AMERICA CHINESE HAMSTER OVARY (CHO) CELLS MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)
TABLE 6 NORTH AMERICA CHINESE HAMSTER OVARY (CHO) CELLS MARKET, BY SYSTEM, 2021-2030 (USD THOUSAND)
TABLE 7 NORTH AMERICA CHINESE HAMSTER OVARY (CHO) CELLS MARKET, BY APPLICATION, 2021-2030 (USD THOUSAND)
TABLE 8 NORTH AMERICA BIOLOGICS IN CHINESE HAMSTER OVARY (CHO) CELLS MARKET, BY APPLICATION, 2021-2030 (USD THOUSAND)
TABLE 9 NORTH AMERICA CHINESE HAMSTER OVARY (CHO) CELLS MARKET, BY END USER, 2021-2030 (USD THOUSAND)
TABLE 10 NORTH AMERICA BIOPHARMACEUTICAL COMPANIES IN CHINESE HAMSTER OVARY (CHO) CELLS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 11 NORTH AMERICA BIOTECHNOLOGY COMPANIES IN CHINESE HAMSTER OVARY (CHO) CELLS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 12 NORTH AMERICA CLINICAL DEVELOPMENT AND MANUFACTURING ORGANIZATIONS IN CHINESE HAMSTER OVARY (CHO) CELLS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 13 NORTH AMERICA CLINICAL RESEARCH ORGANIZATIONS IN CHINESE HAMSTER OVARY (CHO) CELLS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 14 NORTH AMERICA CHINESE HAMSTER OVARY (CHO) CELLS MARKET, BY DISTRIBUTION CHANNEL, 2020-2030 (USD THOUSAND)
TABLE 15 NORTH AMERICA CHINESE HAMSTER OVARY (CHO) CELLS MARKET, BY COUNTRY, 2021-2030 (USD THOUSAND)
TABLE 16 U.S. CHINESE HAMSTER OVARY (CHO) CELLS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 17 U.S. PRODUCT IN CHINESE HAMSTER OVARY (CHO) CELLS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 18 U.S. PRODUCT IN CHINESE HAMSTER OVARY (CHO) CELLS MARKET, BY TYPE, 2021-2030 ASP
TABLE 19 U.S. CHINESE HAMSTER OVARY (CHO) CELLS MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)
TABLE 20 U.S. CHO-K1 IN CHINESE HAMSTER OVARY (CHO) CELLS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 21 U.S. CHO-K1 IN CHINESE HAMSTER OVARY (CHO) CELLS MARKET, BY TYPE, 2021-2030 ASP
TABLE 22 U.S. CHINESE HAMSTER OVARY (CHO) CELLS MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)
TABLE 23 U.S. CHINESE HAMSTER OVARY (CHO) CELLS MARKET, BY SYSTEM, 2021-2030 (USD THOUSAND)
TABLE 24 U.S. CHINESE HAMSTER OVARY (CHO) CELLS MARKET, BY APPLICATION, 2021-2030 (USD THOUSAND)
TABLE 25 U.S. BIOLOGICS IN CHINESE HAMSTER OVARY (CHO) CELLS MARKET, BY APPLICATION, 2021-2030 (USD THOUSAND)
TABLE 26 U.S. CHINESE HAMSTER OVARY (CHO) CELLS MARKET, BY END USER, 2021-2030 (USD THOUSAND)
TABLE 27 U.S. BIOPHARMACEUTICAL COMPANIES IN CHINESE HAMSTER OVARY (CHO) CELLS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 28 U.S. BIOTECHNOLOGY COMPANIES IN CHINESE HAMSTER OVARY (CHO) CELLS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 29 U.S. CLINICAL DEVELOPMENT AND MANUFACTURING ORGANIZATIONS IN CHINESE HAMSTER OVARY (CHO) CELLS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 30 U.S. CLINICAL RESEARCH ORGANIZATIONS IN CHINESE HAMSTER OVARY (CHO) CELLS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 31 U.S. CHINESE HAMSTER OVARY (CHO) CELLS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)
TABLE 32 CANADA CHINESE HAMSTER OVARY (CHO) CELLS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 33 CANADA PRODUCT IN CHINESE HAMSTER OVARY (CHO) CELLS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 34 CANADA PRODUCT IN CHINESE HAMSTER OVARY (CHO) CELLS MARKET, BY TYPE, 2021-2030 ASP
TABLE 35 CANADA CHINESE HAMSTER OVARY (CHO) CELLS MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)
TABLE 36 CANADA CHO-K1 IN CHINESE HAMSTER OVARY (CHO) CELLS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 37 CANADA CHO-K1 IN CHINESE HAMSTER OVARY (CHO) CELLS MARKET, BY TYPE, 2021-2030 ASP
TABLE 38 CANADA CHINESE HAMSTER OVARY (CHO) CELLS MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)
TABLE 39 CANADA CHINESE HAMSTER OVARY (CHO) CELLS MARKET, BY SYSTEM, 2021-2030 (USD THOUSAND)
TABLE 40 CANADA CHINESE HAMSTER OVARY (CHO) CELLS MARKET, BY APPLICATION, 2021-2030 (USD THOUSAND)
TABLE 41 CANADA BIOLOGICS IN CHINESE HAMSTER OVARY (CHO) CELLS MARKET, BY APPLICATION, 2021-2030 (USD THOUSAND)
TABLE 42 CANADA CHINESE HAMSTER OVARY (CHO) CELLS MARKET, BY END USER, 2021-2030 (USD THOUSAND)
TABLE 43 CANADA BIOPHARMACEUTICAL COMPANIES IN CHINESE HAMSTER OVARY (CHO) CELLS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 44 CANADA BIOTECHNOLOGY COMPANIES IN CHINESE HAMSTER OVARY (CHO) CELLS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 45 CANADA CLINICAL DEVELOPMENT AND MANUFACTURING ORGANIZATIONS IN CHINESE HAMSTER OVARY (CHO) CELLS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 46 CANADA CLINICAL RESEARCH ORGANIZATIONS IN CHINESE HAMSTER OVARY (CHO) CELLS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 47 CANADA CHINESE HAMSTER OVARY (CHO) CELLS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)
TABLE 48 MEXICO CHINESE HAMSTER OVARY (CHO) CELLS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 49 MEXICO PRODUCT IN CHINESE HAMSTER OVARY (CHO) CELLS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 50 MEXICO PRODUCT IN CHINESE HAMSTER OVARY (CHO) CELLS MARKET, BY TYPE, 2021-2030 ASP
TABLE 51 MEXICO CHINESE HAMSTER OVARY (CHO) CELLS MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)
TABLE 52 MEXICO CHO-K1 IN CHINESE HAMSTER OVARY (CHO) CELLS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 53 MEXICO CHO-K1 IN CHINESE HAMSTER OVARY (CHO) CELLS MARKET, BY TYPE, 2021-2030 ASP
TABLE 54 MEXICO CHINESE HAMSTER OVARY (CHO) CELLS MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)
TABLE 55 MEXICO CHINESE HAMSTER OVARY (CHO) CELLS MARKET, BY SYSTEM, 2021-2030 (USD THOUSAND)
TABLE 56 MEXICO CHINESE HAMSTER OVARY (CHO) CELLS MARKET, BY APPLICATION, 2021-2030 (USD THOUSAND)
TABLE 57 MEXICO BIOLOGICS IN CHINESE HAMSTER OVARY (CHO) CELLS MARKET, BY APPLICATION, 2021-2030 (USD THOUSAND)
TABLE 58 MEXICO CHINESE HAMSTER OVARY (CHO) CELLS MARKET, BY END USER, 2021-2030 (USD THOUSAND)
TABLE 59 MEXICO BIOPHARMACEUTICAL COMPANIES IN CHINESE HAMSTER OVARY (CHO) CELLS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 60 MEXICO BIOTECHNOLOGY COMPANIES IN CHINESE HAMSTER OVARY (CHO) CELLS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 61 MEXICO CLINICAL DEVELOPMENT AND MANUFACTURING ORGANIZATIONS IN CHINESE HAMSTER OVARY (CHO) CELLS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 62 MEXICO CLINICAL RESEARCH ORGANIZATIONS IN CHINESE HAMSTER OVARY (CHO) CELLS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 63 MEXICO CHINESE HAMSTER OVARY (CHO) CELLS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)
图片列表
FIGURE 1 NORTH AMERICA CHINESE HAMSTER OVARY (CHO) CELLS MARKET: SEGMENTATION
FIGURE 2 NORTH AMERICA CHINESE HAMSTER OVARY (CHO) CELLS MARKET: DATA TRIANGULATION
FIGURE 3 NORTH AMERICA CHINESE HAMSTER OVARY (CHO) CELLS MARKET: DROC ANALYSIS
FIGURE 4 NORTH AMERICA CHINESE HAMSTER OVARY (CHO) CELLS MARKET: REGIONAL VS COUNTRY MARKET ANALYSIS
FIGURE 5 NORTH AMERICA CHINESE HAMSTER OVARY (CHO) CELLS MARKET: COMPANY RESEARCH ANALYSIS
FIGURE 6 NORTH AMERICA CHINESE HAMSTER OVARY (CHO) CELLS MARKET: INTERVIEW DEMOGRAPHICS
FIGURE 7 NORTH AMERICA CHINESE HAMSTER OVARY (CHO) CELLS MARKET: DBMR MARKET POSITION GRID
FIGURE 8 NORTH AMERICA CHINESE HAMSTER OVARY (CHO) CELLS MARKET: MARKET APPLICATION COVERAGE GRID
FIGURE 9 NORTH AMERICA CHINESE HAMSTER OVARY (CHO) CELLS MARKET: VENDOR SHARE ANALYSIS
FIGURE 10 NORTH AMERICA CHINESE HAMSTER OVARY (CHO) CELLS MARKET: SEGMENTATION
FIGURE 11 RISING DEMAND FOR BIOLOGICS AND THERAPEUTIC PROTEINS EXPECTED TO DRIVE THE NORTH AMERICA CHINESE HAMSTER OVARY (CHO) CELLS MARKET GROWTH IN THE FORECAST PERIOD OF 2023 TO 2030
FIGURE 12 TYPE SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE NORTH AMERICA CHINESE HAMSTER OVARY (CHO) CELLS MARKET IN THE FORECAST PERIOD OF 2023 & 2030
FIGURE 13 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF THE NORTH AMERICA CHINESE HAMSTER OVARY (CHO) CELLS MARKET
FIGURE 14 NORTH AMERICA CHINESE HAMSTER OVARY (CHO) CELLS MARKET: BY TYPE, 2022
FIGURE 15 NORTH AMERICA CHINESE HAMSTER OVARY (CHO) CELLS MARKET: BY TYPE, 2023-2030 (USD THOUSAND)
FIGURE 16 NORTH AMERICA CHINESE HAMSTER OVARY (CHO) CELLS MARKET: BY TYPE, CAGR (2023-2030)
FIGURE 17 NORTH AMERICA CHINESE HAMSTER OVARY (CHO) CELLS MARKET: BY TYPE, LIFELINE CURVE
FIGURE 18 NORTH AMERICA CHINESE HAMSTER OVARY (CHO) CELLS MARKET: BY SYSTEM, 2022
FIGURE 19 NORTH AMERICA CHINESE HAMSTER OVARY (CHO) CELLS MARKET: BY SYSTEM, 2023-2030 (USD THOUSAND)
FIGURE 20 NORTH AMERICA CHINESE HAMSTER OVARY (CHO) CELLS MARKET: BY SYSTEM, CAGR (2023-2030)
FIGURE 21 NORTH AMERICA CHINESE HAMSTER OVARY (CHO) CELLS MARKET: BY SYSTEM, LIFELINE CURVE
FIGURE 22 NORTH AMERICA CHINESE HAMSTER OVARY (CHO) CELLS MARKET: BY APPLICATION, 2022
FIGURE 23 NORTH AMERICA CHINESE HAMSTER OVARY (CHO) CELLS MARKET: BY APPLICATION, 2023-2030 (USD THOUSAND)
FIGURE 24 NORTH AMERICA CHINESE HAMSTER OVARY (CHO) CELLS MARKET: BY APPLICATION, CAGR (2023-2030)
FIGURE 25 NORTH AMERICA CHINESE HAMSTER OVARY (CHO) CELLS MARKET: BY APPLICATION, LIFELINE CURVE
FIGURE 26 NORTH AMERICA CHINESE HAMSTER OVARY (CHO) CELLS MARKET: BY END USER, 2022
FIGURE 27 NORTH AMERICA CHINESE HAMSTER OVARY (CHO) CELLS MARKET: BY END USER, 2023-2030 (USD THOUSAND)
FIGURE 28 NORTH AMERICA CHINESE HAMSTER OVARY (CHO) CELLS MARKET: BY END USER, CAGR (2023-2030)
FIGURE 29 NORTH AMERICA CHINESE HAMSTER OVARY (CHO) CELLS MARKET: BY END USER, LIFELINE CURVE
FIGURE 30 NORTH AMERICA CHINESE HAMSTER OVARY (CHO) CELLS MARKET: BY DISTRIBUTION CHANNEL, 2022
FIGURE 31 NORTH AMERICA CHINESE HAMSTER OVARY (CHO) CELLS MARKET: BY DISTRIBUTION CHANNEL, 2023-2030 (USD THOUSAND)
FIGURE 32 NORTH AMERICA CHINESE HAMSTER OVARY (CHO) CELLS MARKET: BY DISTRIBUTION CHANNEL, CAGR (2023-2030)
FIGURE 33 NORTH AMERICA CHINESE HAMSTER OVARY (CHO) CELLS MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE
FIGURE 34 NORTH AMERICA CHINESE HAMSTER OVARY (CHO) CELLS MARKET: SNAPSHOT (2022)
FIGURE 35 NORTH AMERICA CHINESE HAMSTER OVARY (CHO) CELLS MARKET: COMPANY SHARE 2022 (%)
研究方法
Data collection and base year analysis are done using data collection modules with large sample sizes. The stage includes obtaining market information or related data through various sources and strategies. It includes examining and planning all the data acquired from the past in advance. It likewise envelops the examination of information inconsistencies seen across different information sources. The market data is analysed and estimated using market statistical and coherent models. Also, market share analysis and key trend analysis are the major success factors in the market report. To know more, please request an analyst call or drop down your inquiry.
The key research methodology used by DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market and primary (industry expert) validation. Data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Patent Analysis, Pricing Analysis, Company Market Share Analysis, Standards of Measurement, Global versus Regional and Vendor Share Analysis. To know more about the research methodology, drop in an inquiry to speak to our industry experts.
可定制
Data Bridge Market Research is a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customized to include price trend analysis of target brands understanding the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market and product base analysis. Market analysis of target competitors can be analyzed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Fact book) or can assist you in creating presentations from the data sets available in the report.
